Cargando…

Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease

BACKGROUND: ALZ-801 is an orally available, valine-conjugated prodrug of tramiprosate. Tramiprosate, the active agent, is a small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor that was evaluated extensively in preclinical and clinical investigations for the treatment of Alzheimer’s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hey, John A., Yu, Jeremy Y., Versavel, Mark, Abushakra, Susan, Kocis, Petr, Power, Aidan, Kaplan, Paul L., Amedio, John, Tolar, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814546/ https://www.ncbi.nlm.nih.gov/pubmed/29063518 http://dx.doi.org/10.1007/s40262-017-0608-3

Ejemplares similares

Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain
por: Hey, John A., et al.
Publicado: (2018)

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
por: Tolar, Martin, et al.
Publicado: (2020)

Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer’s Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data
por: Kocis, Petr, et al.
Publicado: (2017)

Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression
por: Tolar, Martin, et al.
Publicado: (2021)

APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline
por: Abushakra, Susan, et al.
Publicado: (2020)

A Review on Tramiprosate (Homotaurine) in Alzheimer's Disease and Other Neurocognitive Disorders
por: Manzano, Sagrario, et al.
Publicado: (2020)

Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau
por: Santa-Maria, Ismael, et al.
Publicado: (2007)

AlzPathway: a comprehensive map of signaling pathways of Alzheimer’s disease
por: Mizuno, Satoshi, et al.
Publicado: (2012)

Signature of Alzheimer’s Disease in Intestinal Microbiome: Results From the AlzBiom Study
por: Laske, Christoph, et al.
Publicado: (2022)

Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)
por: Aisen, Paul S., et al.
Publicado: (2011)

AlzPlatform: An Alzheimer’s Disease Domain-Specific Chemogenomics Knowledgebase for Polypharmacology and Target Identification Research
por: Liu, Haibin, et al.
Publicado: (2014)

Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials
por: Wessels, Alette M., et al.
Publicado: (2020)

AlzPharm: integration of neurodegeneration data using RDF
por: Lam, Hugo YK, et al.
Publicado: (2007)

TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease
por: Salloway, Stephen, et al.
Publicado: (2023)

AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery
por: Zhou, Yadi, et al.
Publicado: (2021)

Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer’s disease brain extracts
por: Sandberg, Anders, et al.
Publicado: (2022)

Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings
por: Wessels, Alette M., et al.
Publicado: (2023)

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial
por: Pontecorvo, Michael J., et al.
Publicado: (2022)

CAD-ALZ: A Blockwise Fine-Tuning Strategy on Convolutional Model and Random Forest Classifier for Recognition of Multistage Alzheimer’s Disease
por: Abbas, Qaisar, et al.
Publicado: (2023)

Understanding the pharmacokinetics of prodrug and metabolite
por: Cho, Seungil, et al.
Publicado: (2018)

Meta Analysis of Human AlzGene Database: Benefits and Limitations of Using C. elegans for the Study of Alzheimer's Disease and Co-morbid Conditions
por: Vahdati Nia, Behrad, et al.
Publicado: (2017)

The clinical use of blood-test factors for Alzheimer’s disease: improving the prediction of cerebral amyloid deposition by the QPLEX(TM)Alz plus assay kit
por: Kim, Haeng Jun, et al.
Publicado: (2021)

Antidepressant Effects of (+)-MK-801 and (-)-MK-801 in the Social Defeat Stress Model
por: Yang, Bangkun, et al.
Publicado: (2016)

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial
por: Shcherbinin, Sergey, et al.
Publicado: (2022)

Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition
por: Park, Jong-Chan, et al.
Publicado: (2021)

A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early AD
por: McNett, Sienna D., et al.
Publicado: (2023)

RTP801/REDD1 contributes to neuroinflammation severity and memory impairments in Alzheimer’s disease
por: Pérez-Sisqués, Leticia, et al.
Publicado: (2021)

Pharmacokinetics of Temsavir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment
por: Sevinsky, Heather, et al.
Publicado: (2017)

Synthesis, Screening and Pharmacokinetic Evaluation of Potential Prodrugs of Bupropion. Part One: In Vitro Development
por: O’Byrne, Paul Matthew, et al.
Publicado: (2014)

Evaluation of the Potential Pharmacokinetic Interactions Between Vixotrigine and an Oral Contraceptive
por: Zhao, Yuan, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282
por: O’Donnell, John, et al.
Publicado: (2020)

AlzEye: longitudinal record-level linkage of ophthalmic imaging and hospital admissions of 353 157 patients in London, UK
por: Wagner, Siegfried Karl, et al.
Publicado: (2022)

Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of Vixotrigine in Healthy Volunteers
por: Naik, Himanshu, et al.
Publicado: (2020)

Synthesis, Biological Evaluation, and Pharmacokinetic Study of Novel Liguzinediol Prodrugs
por: Liu, Zheng, et al.
Publicado: (2013)

Safety, pharmacokinetics, and pharmacodynamics of Gln‐1062, a prodrug of galantamine
por: Bakker, Charlotte, et al.
Publicado: (2020)

Prodrugs for Amines
por: Simplício, Ana L., et al.
Publicado: (2008)

Pharmacokinetics and local tissue response to local instillation of vocacapsaicin, a novel capsaicin prodrug, in rat and rabbit osteotomy models
por: Knotts, Tarra, et al.
Publicado: (2022)

Scrap of gloveboxes No. 801-W and No. 802-W
por: Ohuchi, S, et al.
Publicado: (2002)

Inside the electronics barrack of the experiment R801
Publicado: (1974)

Memantine prodrug as a new agent for Alzheimer’s Disease
por: Sestito, Simona, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8knbm0uctm5f2ekk6junt1p1e8